The therapeutic role of ANGPTL3 inhibition for hyperlipidaemia has recently been reviewed [20] The well-established evidence for variants impairing the function of PCSK9 and APOC3 as being protective against hyperlipidaemia is fuelling research into developing strategies to find novel ways to antagonise PCSK9 and lower apoC-III [21, 22]. This evidence concerns the gene APOC3 and hyperlipidemia.